Patients with Pompe disease are facing canceled infusions amid continuing supply disruptions involving Sanofi’s treatments, Lumizyme and Nexviazyme. The company says manufacturing issues at its Ireland facility have contributed to shortages, with shipping delays potentially interrupting treatment for some U.S. patients through the end of November 2026.
Pompe disease is a rare condition in which patients lack an enzyme needed to break down glycogen. Its accumulation damages muscles and can affect breathing and heart function. Sanofi’s therapies replace the missing enzyme and are typically administered every two weeks. Untreated disease can be fatal.
The FDA inspected the Irish facility in January 2026 and identified manufacturing violations involving two unrelated drugs. In a June 22 warning letter, the agency said Sanofi had not adequately addressed underlying compliance failures. Sanofi says work to resolve those concerns has contributed to the disruption, but maintains that the affected Pompe medicines have no quality problems.
Patients and advocates have raised concerns about advance notice and transparency. Monique Griffin, a 51-year-old Florida resident who uses a wheelchair, had an infusion canceled and fears declining strength and breathing capacity. Minnesota parent Chelsey McGee says her 10-year-old son’s infusions have continued, but worries interruptions could affect his heart.
Sanofi says it has updated patients, clinicians and advocacy organizations as the situation developed, and is prioritizing the most vulnerable patients. It reports progress restoring supplies in some countries. The company advises patients to consult health professionals before considering alternatives, emphasizing that the medicines are not interchangeable. The FDA says it has offered assistance to help maintain access to treatment.
Other potential treatments, including gene therapies from AskBio and Astellas Pharma, are in clinical trials. For patients currently dependent on regular enzyme replacement infusions, however, the immediate concern remains whether scheduled treatment can continue while Sanofi works to stabilize supply.